Factor XIa inhibition is being evaluated as a potential new tool for preventing recurrent cerebrovascular events.
Trial Shows Promise for a New Antithrombotic Approach
Recent demographic shifts show a rising tide of hypertension, diabetes and obesity, which together forecast a higher burden of brain attacks in the next decade. Current regimens rely on aspirin, clopidogrel or ticagrelor, yet patients still face a tangible risk of another incident despite those medicines. The search for a mechanism that curbs clot formation without markedly increasing bleed risk has sharpened in recent years.
Related: FDA Approves New Treatments for Brain Disorders
The phase 3 OCEANIC‑STROKE trial (NCT05686070) examined the oral agent asundexian, a selective inhibitor of activated factor XI. Researchers added the drug to standard antiplatelet therapy in participants who had suffered a recent non‑cardioembolic event or a high‑risk transient ischemic attack. Over the study period, the combination cut recurrent ischemic strokes by 26% compared with antiplatelet therapy alone.
These findings have sparked interest across neurology circles, as they represent one of the first late‑stage evaluations of a truly novel clot‑blocking pathway. The mechanism targets factor XI, a protein that sits upstream of the common cascade and may be less tied to bleeding when blocked.
Expert Views on the Emerging Strategy
To put the results in context, Seemant Chaturvedi, MD, the Stewart J. Greenebaum Endowed Professor in Stroke Neurology at University of Maryland School of Medicine, discussed the trial on a recent interview. He noted that the persistent gap in preventing recurrence has been a “real” clinical challenge, even as antiplatelet drugs have improved over two decades.
Related: Australia trails as road safety improves globally
Chaturvedi explained that factor XIa inhibition works by dampening the intrinsic pathway, which is thought to contribute to clot propagation without heavily affecting the protective platelet plug. He added that the trial’s safety profile aligns with the hypothesis that this target can separate thrombosis from hemorrhage.
He also highlighted that the aging population will likely expand the pool of patients who could benefit from a safer, more effective regimen. In his view, the timing is right for a shift because health systems are already grappling with rising rates of metabolic disease that fuel cerebrovascular risk.